HSDT
Helius Medical Technologies Inc Class A
2.60$
-8.4%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 100.0% | 100.0% | 100.0% | 97.2% | 96.9% | 70.0% | 71.6% | 89.3% | 96.6% | 94.9% | 96.7% | 10.3% | |
| 34.4% | 65.4% | 65.4% | 81.7% | 91.9% | 52.8% | 50.9% | 78.0% | 84.2% | 67.4% | 30.7% | 2.4% | |
| 65.5% | 65.4% | 65.4% | 81.7% | 91.9% | 52.8% | 50.9% | 78.0% | 84.2% | 67.4% | 30.7% | 2.4% | |
| 0.7% | 9.9% | 9.9% | 10.3% | 1.0% | 5.5% | 3.5% | 1.8% | 2.0% | 8.3% | 17.9% | – | |
| – | – | – | – | 1.4% | 5.8% | 5.9% | 3.4% | 3.4% | 5.9% | 30.8% | 0.4% | |
| – | – | – | 2.5% | 2.0% | 12.2% | 7.4% | 2.9% | 2.6% | – | – | – | |
| – | – | – | – | – | 12.0% | 11.6% | 5.4% | 0.0% | – | – | – | |
| – | – | – | – | – | 5.6% | 8.0% | 2.4% | 0.8% | 0.3% | – | 64.7% | |
| 228.5% | 100.4% | 100.4% | 210.0% | 64.6% | 43.6% | 40.9% | 20.2% | 52.8% | 69.4% | 70.1% | 1.0% | |
| 98.5% | 57.7% | 57.7% | 210.0% | 64.6% | 36.7% | 37.0% | 18.8% | 11.5% | 24.4% | 61.1% | 1.0% | |
| – | – | 110.7% | 14.8% | 49.5% | 1.7% | 0.9% | 0.0% | 0.3% | 0.6% | 0.3% | – | |
| 98.5% | 54.0% | 53.5% | 51.1% | 8.6% | 16.2% | 11.4% | 7.6% | 3.6% | 6.9% | 24.6% | 0.6% | |
| 130.0% | 42.7% | – | – | – | – | – | – | – | – | – | – | |
| -128.5% | -0.4% | -0.4% | -110.0% | 35.4% | 56.4% | 59.1% | 79.8% | 47.2% | 30.6% | 29.9% | 99.0% | |
| -1,596.9% | -651.0% | -651.0% | -974.7% | -341.4% | -1,012.6% | -1,816.1% | -971.7% | -874.1% | -2,079.5% | -4,847.5% | -69.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 7.3% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.